Compounds that select against the tetracycline-resistance efflux pump

Laura K. Stone; Michael Baym; Tami D. Lieberman; Remy Chait; Jon Clardy; Kishony Roy

doi:10.1038/nchembio.2176

Compounds that select against the tetracycline-resistance efflux pump

Laura K. Stone, Michael Baym, Tami D. Lieberman, Remy Chait, Jon Clardy, Kishony Roy

Technion - Israel Institute of Technology

Research output: Contribution to journal › Article › peer-review

Abstract

We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline-resistance efflux pump in Escherichia coli and identified two hits, β-thujaplicin and disulfiram. Treating a tetracycline-resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline.

Original language	English
Pages (from-to)	902-904
Number of pages	3
Journal	Nature Chemical Biology
Volume	12
Issue number	11
DOIs	https://doi.org/10.1038/nchembio.2176
State	Published - 1 Nov 2016

All Science Journal Classification (ASJC) codes

Molecular Biology
Cell Biology

Access to Document

10.1038/nchembio.2176

Cite this

@article{8f7554d52ab94bad851df386f07f4b88,

title = "Compounds that select against the tetracycline-resistance efflux pump",

abstract = "We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline-resistance efflux pump in Escherichia coli and identified two hits, β-thujaplicin and disulfiram. Treating a tetracycline-resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline.",

author = "Stone, \{Laura K.\} and Michael Baym and Lieberman, \{Tami D.\} and Remy Chait and Jon Clardy and Kishony Roy",

year = "2016",

month = nov,

day = "1",

doi = "10.1038/nchembio.2176",

language = "الإنجليزيّة",

volume = "12",

pages = "902--904",

journal = "Nature Chemical Biology",

issn = "1552-4450",

publisher = "Nature Research",

number = "11",

}

TY - JOUR

T1 - Compounds that select against the tetracycline-resistance efflux pump

AU - Stone, Laura K.

AU - Baym, Michael

AU - Lieberman, Tami D.

AU - Chait, Remy

AU - Clardy, Jon

AU - Roy, Kishony

PY - 2016/11/1

Y1 - 2016/11/1

N2 - We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline-resistance efflux pump in Escherichia coli and identified two hits, β-thujaplicin and disulfiram. Treating a tetracycline-resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline.

AB - We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline-resistance efflux pump in Escherichia coli and identified two hits, β-thujaplicin and disulfiram. Treating a tetracycline-resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline.

UR - http://www.scopus.com/inward/record.url?scp=84988422072&partnerID=8YFLogxK

U2 - 10.1038/nchembio.2176

DO - 10.1038/nchembio.2176

M3 - مقالة

SN - 1552-4450

VL - 12

SP - 902

EP - 904

JO - Nature Chemical Biology

JF - Nature Chemical Biology

IS - 11

ER -

Compounds that select against the tetracycline-resistance efflux pump

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this